Quarterly report pursuant to Section 13 or 15(d)

Segments (Details)

Segments (Details) (USD $)	3 Months Ended
Segments (Details) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	$ 1,835,422us-gaap_SalesRevenueNet	$ 626,631us-gaap_SalesRevenueNet
Lymphoseek license revenue	83,333us-gaap_LicensesRevenue	0us-gaap_LicensesRevenue
Grant and other revenue	189,701us-gaap_RevenueFromGrants	125,173us-gaap_RevenueFromGrants
Total revenue	2,108,456us-gaap_Revenues	751,804us-gaap_Revenues
Research and development expenses	(3,981,288)us-gaap_ResearchAndDevelopmentExpense	(5,226,794)us-gaap_ResearchAndDevelopmentExpense
Selling, general and administrative expenses, excluding depreciation and amortization2	(5,380,000)
Depreciation and amortization	(149,822)	(111,270)
Loss from operations	(7,816,057)us-gaap_OperatingIncomeLoss	(8,579,043)us-gaap_OperatingIncomeLoss
Nonoperating Income (Expense)	787,059us-gaap_NonoperatingIncomeExpense
Income (Loss) from Equity Method Investments	(262,227)	0
Net loss attributable to common stockholders	(7,337,125)	(11,740,553)
Assets	10,917,909us-gaap_Assets		11,920,180us-gaap_Assets
Capital expenditures	0
United States
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	1,831,000
Assets	10,418,933
International
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	6,000
Assets	498,976
Diagnostics
Segment Reporting Information [Line Items]
Lymphoseek license revenue	83,333
Grant and other revenue	189,701
Total revenue	2,108,456
Research and development expenses	(3,895,000)
Selling, general and administrative expenses, excluding depreciation and amortization2	(2,042,000)
Depreciation and amortization	(72,000)
Loss from operations	(4,314,527)
Nonoperating Income (Expense)	0
Income (Loss) from Equity Method Investments	0
Net loss attributable to common stockholders	(4,314,527)
Capital expenditures	0
Diagnostics \| United States
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	1,831,000
Assets	3,333,851
Diagnostics \| International
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	6,000
Assets	496,311
Therapeutics
Segment Reporting Information [Line Items]
Lymphoseek license revenue	0
Grant and other revenue	0
Total revenue	0
Research and development expenses	(86,000)
Selling, general and administrative expenses, excluding depreciation and amortization2	(14,000)
Depreciation and amortization	0
Loss from operations	(100,380)
Nonoperating Income (Expense)	0
Income (Loss) from Equity Method Investments	0
Net loss attributable to common stockholders	(146,380)
Capital expenditures	0
Therapeutics \| United States
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	0
Assets	7,409
Therapeutics \| International
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	0
Assets	0
Corporate
Segment Reporting Information [Line Items]
Lymphoseek license revenue	0
Grant and other revenue	0
Total revenue	0
Research and development expenses	0
Selling, general and administrative expenses, excluding depreciation and amortization2	(3,324,000)
Depreciation and amortization	(78,000)
Loss from operations	(3,401,150)
Nonoperating Income (Expense)	786,832
Income (Loss) from Equity Method Investments	(262,227)
Net loss attributable to common stockholders	(2,876,318)
Capital expenditures	0
Corporate \| United States
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	0
Assets	7,077,673
Corporate \| International
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	0
Assets	$ 2,665